SUMMARY The incidence of sepsis, mortality due to sepsis, total mortality, and minor infections was evaluated in a group of 46 premature newborn infants who were treated with intravenous immunoglobulins. They were compared with an untreated control group. No significant differences were observed between the two groups. 5-30x 109/l), band/total neutrophils ratio (normal value <0-2); platelet count (normal value >100x109/l); serum concentration of IgM (normal value <0-30 g/l); semiquantitative latex assay of C-reactive protein (normal value <0-008 g/l) serum fibrinogen concentration (normal range 2-2-50 g/l); haptoglobin (normal value <0-40 g/1), and serum concentration of a-i-acid glycoprotein (normal value <0-25 g/l).
Bacterial infections during the first few days of life remain an important cause of neonatal morbidity and mortality, especially in the premature newborn.' It has been reported that incidence of neonatal sepsis and its mortality rate decrease by the intravenous administration of polyvalent human gammaglobulins with an intact crystallisable fragment.2 3 We report a randomised, controlled, blind study that was performed to determine whether intravenous immunoglobulins are able to prevent sepsis in premature newborn infants. Patients We excluded six treated infants: three underwent an exchange transfusion, two died of severe respiratory distress syndrome on the 2nd and 3rd day of life respectively after a single dose of immunoglobulin, and one had suspected prenatal infection. Eight control babies were also excluded: two had an exchange transfusion, three died of severe respiratory distress syndrome on the 3rd day of life, one died of respiratory distress syndrome and intracranial haemorrhage on the 10th day, and two had suspected prenatal infection. Sepsis was not the reason for the exchange transfusion or the cause of the death in any infant. The Student's t test and x2 analysis were used for statistical evaluation.
Results
There were no significant differences between the No adverse effects were noted after immunoglobulin transfusions in our subjects. The higher incidence of hypocalcaemia in the treated group cannot be clearly explained, but if this is confirmed it makes the routine use of intravenous immunoglobulin even more questionable. 
